In testosterone-stimulated MCF-7aro breast cancer cells, micromolar exemestane reduced DNA synthesis and shifted cell-cycle distribution toward G0/G1 at 3 days and G2/M at 6 days. Viability effects depended on concentration and exposure time; the lower concentrations did not reduce viability until 9 days. [2]
In the same cell model, 10–15 µM exemestane increased the Annexin V-positive/7-AAD-negative fraction after 6 days. No Annexin V difference was reported after 3 days, indicating a delayed response under these conditions. [2]
Aromatase inhibition in recombinant-enzyme S9 fractions
Biochemical assay · S9 fraction from HEK293 cells overexpressing wild-type human CYP19A1 [1]
Parent exemestane inhibited estrone formation in a cell-free enzyme preparation. The reported potency depends on substrate concentration and assay design.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.01–30 µM for parent-drug IC50; screening at 1 and 10 µM
- Exposure duration
- 45 minutes at 37°C; selected potency series without the 30-minute preincubation step
- Method
- Estrone formation quantified by UPLC-MS; 125 µg S9 protein, 5 µM androstenedione and NADPH-regeneration system in 50 µL
- Vehicle
- Final 1.2% methanol and 0.4% DMSO
- Co-treatment
- No therapeutic combination; other compounds were tested separately.
- Reported limits
- Chemical purity and lot-specific identity data are not supplied in the selected methods.
Methods and source locations
Compound reported in the paper: Exemestane; Compound label in the paper: EXE
Compound-level evidence for the reported material and model; no validation of Adooq material, lot purity or formulation.
Materials and Methods: Chemicals and Materials, Inhibition Assays of Aromatase Activity, IC50 and IC50 Shift Determinations, Data Analysis; Results paragraphs 1–3; Table 1 footnote a
Inhibition of aromatase-dependent estrone formation: UPLC-MS estrone assay; three-parameter concentration-response fitting — Table 1 EXE row and footnote a; Methods: IC50 determinations
Estrone formation relative to no-inhibitor control: 45-minute S9 assay; screening performed in triplicate experiments — Results first paragraph; Figure 1 caption; Methods: Inhibition Assays
Inhibition of estrone formation in human ovarian S9
Biochemical assay · Pooled S9 fractions from three normal human ovarian tissue donors, aged 30–40 years; ex vivo biochemical preparation [1]
Parent exemestane inhibited estrone formation in pooled human ovarian tissue S9. This is a tissue-enzyme assay, not treatment of women or an animal experiment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 and 10 µM
- Exposure duration
- 45 minutes at 37°C
- Method
- UPLC-MS estrone assay using 300 µg pooled ovarian S9 protein and 5 µM androstenedione; screening conditions otherwise as described for the enzyme assay
- Vehicle
- Final 1.2% methanol and 0.4% DMSO under the referenced assay conditions
- Co-treatment
- None; parent drug and metabolites screened separately.
- Reported limits
- Pooling prevents donor-level response estimates.
Methods and source locations
Compound reported in the paper: Exemestane; Compound label in the paper: EXE
Compound-level evidence for the reported material and model; no validation of Adooq material, lot purity or formulation.
Methods: Anti-aromatase Activity Determinations in Ovarian Tissue and Inhibition Assays; Results second paragraph; Figure 2 caption
Estrone formation versus uninhibited assay: UPLC-MS; triplicate experiments on pooled S9 (three donors) — Results ovarian-tissue paragraph; Figure 2 caption
Growth and cell-cycle effects in MCF-7aro cells
Cell-based study · ER-positive, aromatase-overexpressing MCF-7aro human breast cancer cells in steroid-depleted medium with 1 nM testosterone [2]
Exemestane reduced DNA synthesis and altered cell-cycle distribution, while viability effects depended on dose and exposure time.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2.5–15 µM for viability and DNA synthesis; 2.5–10 µM for cell-cycle analysis
- Exposure duration
- Viability: 2, 3, 6 and 9 days; DNA synthesis shown at 3, 6 and 9 days; cell cycle: 3 and 6 days; medium and drug refreshed every 3 days
- Method
- MTT, LDH release, tritiated-thymidine incorporation and PI flow cytometry
- Vehicle
- 0.05% DMSO in the 1 nM testosterone control
- Co-treatment
- None; testosterone is assay substrate and proliferation stimulus.
- Reported limits
- No extrapolation to clinical exposure or all ER-positive breast cancer cells.
Methods and source locations
Compound reported in the paper: Exemestane; Compound label in the paper: exemestane
Compound-level evidence for the reported material and model; no validation of Adooq material, lot purity or formulation.
Results: Cell viability and cell proliferation; Cell cycle analysis; Figure 2A–E; Methods: Cell culture, Cell viability and cell proliferation, Cell cycle analysis, Statistical analysis
G0/G1 cell fraction after 3 days: PI flow cytometry; three independent experiments performed in triplicate — Results: Cell cycle analysis; Figure 2D and caption
G2/M cell fraction after 6 days: PI flow cytometry; three independent experiments performed in triplicate — Results: Cell cycle analysis; Figure 2E and caption
DNA synthesis, metabolic viability and membrane integrity: Thymidine incorporation, MTT and LDH assays — Results: Cell viability and cell proliferation; Figure 2A–C and caption
Delayed Annexin V response in MCF-7aro cells
Cell-based study · MCF-7aro cells with 1 nM testosterone; adherent and non-adherent cells pooled for flow analysis [2]
Exemestane increased the early-apoptotic Annexin V-positive/7-AAD-negative fraction after prolonged exposure. No difference was reported at 3 days.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5–15 µM
- Exposure duration
- 3, 6 and 9 days; medium and drug refreshed every 3 days
- Method
- Annexin V-PE/7-AAD flow cytometry with testosterone/vehicle control and 1 µM staurosporine positive control (14 hours)
- Vehicle
- 0.05% DMSO in shared control
- Co-treatment
- None in the selected experiment.
- Reported limits
- The 3-day null result is described as data not shown; no numerical estimate is available.
Methods and source locations
Compound reported in the paper: Exemestane; Compound label in the paper: exemestane
Compound-level evidence for the reported material and model; no validation of Adooq material, lot purity or formulation.
Results: Analysis of cell death, Annexin V paragraph; Table 1 and footnote; Methods: Cell culture and Analysis of apoptosis
Annexin V+/7-AAD− fraction after 6 days: Flow cytometry; three independent experiments done in triplicate — Table 1, 6 DAYS, Annexin V+/7-AAD− row and footnote
Annexin V response after 3 days: Annexin V-PE assay — Results: Analysis of cell death, first paragraph